The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | The outcomes of patients with AL amyloidosis and end-stage renal disease
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the outcomes of patients with light chain (AL) amyloidosis and end-stage renal disease (ESRD). A retrospective study from three European centers collected data from patients starting dialysis after chemotherapy for AL amyloidosis, with the results demonstrating a long survival post-dialysis but no significant improvement in overall survival (OS) compared to data from before 2018. Advanced bone marrow involvement, high light chain levels, and heart involvement were associated with poorer outcomes. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
